ZC3HC1 Knockout cell line (A549)

CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.

ZC3HC1 (zinc finger C3HC-type containing 1) encodes an F-box-containing protein that functions as a component of an SCF-type E3 ubiquitin ligase complex. The complex regulates cell-cycle progression by targeting cyclin B1 for ubiquitin-mediated degradation, thereby controlling the transition from G2 phase to mitosis. ZC3HC1 therefore contributes to regulation of cell-cycle timing through targeted protein degradation.

A549 is a human lung cancer cell line established in 1972 from an explanted lung tumor of a 58-year-old male patient. The cells exhibit characteristics of alveolar type II pulmonary epithelial cells, including the ability to synthesize lecithin through the cytidine diphosphocholine pathway. A549 cells have been described as originating from lung adenocarcinoma and are widely used as a model for studying lung cancer biology, pulmonary epithelial function, drug responses, and respiratory-related research.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.